# US 2018/0022741 A1 · Compositions, formulations and methods for treating ocular diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022741 A1
- Document ID: US20180022741A1
- Status: Published application
- Kind: A1
- Application number: 15/443,622
- Filed: 2017-02-27
- Published: 2018-01-25
- Earliest claimed: 2013-03-15
- Assignees: Aerpio Therapeutics Inc.
- Applicants: Aerpio Therapeutics, Inc.
- Inventors: Kevin Peters; Robert Shalwitz; John Janusz; Alexander Smith
- Web page: https://patentgrep.com/patent/US20180022741A1

## CPC

- C07D 417/12: linked by a chain containing hetero atoms as chain links
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 31/426: 1,3-Thiazoles
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/428: condensed with carbocyclic rings
- A61K 31/433: Thidiazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/497: containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/538: ortho- or peri-condensed with carbocyclic ring systems
- A61K 38/179: {for growth factors; for growth regulators}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- C07D 277/28: Radicals substituted by nitrogen atoms
- C07D 277/30: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 277/56: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 277/60: condensed with carbocyclic rings or ring systems
- C07D 277/64: with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07K 16/22: against growth factors {; against growth regulators}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.

## Claims

### Claim at position 1

1-54. (canceled)

### Claim 55

A method of treating a condition, the method comprising administering to a subject in need thereof:
a) a therapeutically-effective amount of a Tie-2 activator or a pharmaceutically-acceptable salt thereof; and
b) a therapeutically-effective amount of an anti-VEGF binding agent.

### Claim 56 (depends on 55)

The method of claim 55, wherein the Tie-2 activator binds a phosphatase.

### Claim 57 (depends on 55)

The method of claim 55, wherein the Tie-2 activator inhibits a phosphatase.

### Claim 58 (depends on 55)

The method of claim 55, wherein the therapeutically-effective amount of the Tie-2 activator is about 5 mg to about 60 mg.

### Claim 59 (depends on 55)

The method of claim 55, wherein the therapeutically-effective amount of the Tie-2 activator is about 15 mg.

### Claim 60 (depends on 55)

The method of claim 55, wherein the therapeutically-effective amount of the Tie-2 activator is about 30 mg.

### Claim 61 (depends on 55)

The method of claim 55, wherein the therapeutically-effective amount of the anti-VEGF binding agent is about 0.5 mg to about 50 mg.

### Claim 62 (depends on 55)

The method of claim 55, wherein the administration is intravitreal.

### Claim 63 (depends on 55)

The method of claim 55, wherein the administration is subcutaneous.

### Claim 64 (depends on 55)

The method of claim 55, wherein the subject is human.

### Claim 65 (depends on 55)

The method of claim 55, wherein the condition is an ocular condition.

### Claim 66 (depends on 55)

The method of claim 55, wherein the condition is diabetic macular edema.

### Claim 67 (depends on 55)

The method of claim 55, wherein the condition is diabetic retinopathy.

### Claim 68 (depends on 55)

The method of claim 55, wherein the condition is macular degeneration.

### Claim 69 (depends on 55)

The method of claim 55, wherein the condition is vascular leak.

### Claim 70 (depends on 55)

The method of claim 55, wherein the condition is glaucoma.

### Claim 71 (depends on 55)

The method of claim 55, wherein the condition is cancer.

### Claim 72

A method of treating a condition, the method comprising administering to a subject in need thereof:
a) a therapeutically-effective amount of a HPTP-β binding agent or a pharmaceutically-acceptable salt thereof; and
b) a therapeutically-effective amount of an anti-VEGF binding agent.

### Claim 73 (depends on 72)

The method of claim 72, wherein the HPTP-β binding agent is an inhibitor of HPTP-β.

### Claim 74 (depends on 72)

The method of claim 72, wherein the HPTP-β binding agent inhibits a phosphatase.

### Claim 75 (depends on 72)

The method of claim 72, wherein the therapeutically-effective amount of the HPTP-β binding agent is about 5 mg to about 60 mg.

### Claim 76 (depends on 72)

The method of claim 72, wherein the therapeutically-effective amount of the HPTP-β binding agent is about 15 mg.

### Claim 77 (depends on 72)

The method of claim 72, wherein the therapeutically-effective amount of the HPTP-β binding agent is about 30 mg.

### Claim 78 (depends on 72)

The method of claim 72, wherein the therapeutically-effective amount of the anti-VEGF binding agent is about 0.5 mg to about 50 mg.

### Claim 79 (depends on 72)

The method of claim 72, wherein the administration is intravitreal.

### Claim 80 (depends on 72)

The method of claim 72, wherein the administration is subcutaneous.

### Claim 81 (depends on 72)

The method of claim 72, wherein the subject is human.

### Claim 82 (depends on 72)

The method of claim 72, wherein the condition is an ocular condition.

### Claim 83 (depends on 72)

The method of claim 72, wherein the condition is diabetic macular edema.

### Claim 84 (depends on 72)

The method of claim 72, wherein the condition is diabetic retinopathy.

### Claim 85 (depends on 72)

The method of claim 72, wherein the condition is macular degeneration.

### Claim 86 (depends on 72)

The method of claim 72, wherein the condition is vascular leak.

### Claim 87 (depends on 72)

The method of claim 72, wherein the condition is glaucoma.

### Claim 88 (depends on 72)

The method of claim 72, wherein the condition is cancer.
